70
Participants
Start Date
June 30, 2010
Primary Completion Date
December 31, 2014
Study Completion Date
July 31, 2015
Carboplatin
Carboplatin AUC=6IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
Pemetrexed
Pemetrexed 500mg/m² IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
Panitumumab
Panitumumab 9mg/kg IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
Center for Cancer and Blood Disorders, Bethesda
National Capital Clinical Research Consortium, Bethesda
Peninsula Cancer Institute, Newport News
Northeast Georgia Medical Center, Gainesville
Medical Oncology Associates of Augusta, Augusta
Florida Hospital Cancer Institute, Orlando
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, PLLC, Nashville
Baptist Hospital East, Louisville
Norton Cancer Institute, Louisville
Oncology Hematology Care, Cincinnati
Cancer Centers of Southwest Oklahoma, Lawton
Portsmouth Regional Hospital, Portsmouth
Collaborators (1)
Amgen
INDUSTRY
SCRI Development Innovations, LLC
OTHER